TY - JOUR
T1 - Technological challenges of biomembrane-coated top-down cancer nanotherapy
AU - Ravasco, João M.J.M.
AU - Paiva-Santos, Ana Cláudia
AU - Conde, João
N1 - Funding Information:
J.M.J.M.R., J.C. and A.C.P.S. acknowledge the financial support from the Fundac\u00E3o para a Ci\u00EAncia e a Tecnologia I.P. (FCT)-Research and Development Project grant PTDC/BTM-MAT/4738/2020. J.C. acknowledges financial support from the European Research Council-ERC Starting Grant 848325. The authors thank C. Alvarez-Lorenzo and P. Makvandi for their input and critical revision of this article.
Publisher Copyright:
© Springer Nature Limited 2023.
PY - 2023/3
Y1 - 2023/3
N2 - Cancer nanotherapy suffers from low-yield delivery that is imposed by tumour pathophysiological barriers. Top-down drug delivery strategies, including exosomes and cell membrane-coated particles, can improve safety and efficacy owing to the innate biointerfacial properties of these platforms. Here, we discuss the technological challenges that need to be overcome for their clinical implementation.
AB - Cancer nanotherapy suffers from low-yield delivery that is imposed by tumour pathophysiological barriers. Top-down drug delivery strategies, including exosomes and cell membrane-coated particles, can improve safety and efficacy owing to the innate biointerfacial properties of these platforms. Here, we discuss the technological challenges that need to be overcome for their clinical implementation.
UR - http://www.scopus.com/inward/record.url?scp=85156216006&partnerID=8YFLogxK
U2 - 10.1038/s44222-022-00008-2
DO - 10.1038/s44222-022-00008-2
M3 - Comment/debate
AN - SCOPUS:85156216006
SN - 2731-6092
VL - 1
SP - 156
EP - 158
JO - Nature Reviews Bioengineering
JF - Nature Reviews Bioengineering
IS - 3
M1 - 1999
ER -
